Claims for Patent: 12,336,980

Summary for Patent: 12,336,980

Title:	Dosing regimen for a selective S1P1 receptor agonist
Abstract:	The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimmo)-3-o-tolyl-thiazolidin-4-one.
Inventor(s):	Jasper Dingemanse, Matthias Hoch, Andreas Krause
Assignee:	Vanda Pharmaceuticals Inc
Application Number:	US18/046,492
Patent Claims:	1. A method of treating a human subject, diagnosed with multiple sclerosis, who has been orally administered once-daily titrating doses, successively over a period of two weeks, of a compound that is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz [Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one or a pharmaceutically acceptable salt thereof, which successive titrating doses are 2 mg on days 1 and 2; 3 mg of on days 3 and 4; 4 mg on days 5 and 6; 5 mg on day 7; 6 mg on day 8; 7 mg on day 9; 8 mg on day 10; and 9 mg on day 11, and 10 mg on days 12, 13, and 14, comprising: administering, starting on the day following the last titrating dose, 20 mg of said compound. 2. The method of claim 1, wherein the multiple sclerosis is relapsing multiple sclerosis. 3. The method of claim 2, wherein the multiple sclerosis is relapsing-remitting multiple sclerosis.